安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- HIGHLIGHTS OF PRESCRIBING INFORMATION - HALAVEN
FULL PRESCRIBING INFORMATION: CONTENTS 1 INDICATIONS AND USAGE 1 1 Metastatic Breast Cancer 1 2 Liposarcoma 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Dose 2 2 Dose Modification 2 3 Instructions for Preparation and Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5 1 Neutropenia
- This label may not be the latest approved by FDA. For current labeling . . .
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1 1 Metastatic Breast Cancer HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease Prior therapy should have included an anthracycline and a taxane
- Eribulin (Halaven): a new, effective treatment for women with heavily . . .
Only 5% of patients with breast cancer have overt metastatic disease at diagnosis, but at least 30% of those initially diagnosed with early breast cancer will later relapse 1, 2 Survival has also improved for these women with metastatic breast cancer, 3 with a 5-year survival rate of about 23%, 1 but metastatic breast cancer remains
- Eribulin Improves Survival of Women with Metastatic Breast Cancer
Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE Based on these findings, the FDA approved eribulin last November for women with metastatic disease who have already undergone at least two previous
- Eisai Announces Real-World Data on the Effectiveness of HALAVEN . . .
The study was a retrospective, multi-site patient chart review study conducted across oncology practices in the United States and included mBC patients (n=513) who had initiated treatment with HALAVEN, as per U S Prescribing Information, between 2011 and 2017 Data were extracted by prescribing physicians from individual patients' electronic health records and captured via an electronic case
- Advances in the Management of HR+ HER2– Ultralow and -Low Metastatic . . .
T-DXd is approved for adult patients with unresectable or metastatic HER2-low breast cancer after 1 or more lines of chemotherapy based on results from the Patients were treated with SG or single-agent chemotherapy (eribulin, vinorelbine, gemcitabine, or capecitabine) Of the 543 patients, 40% were HER2 IHC 0+ and 52% were HER2 low
- 259P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer . . .
Breast cancer (BC) with low-level HER2 expression (HER2-low) is defined by an immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification or excess gene copy number as measured by in situ hybridization (ISH) HER2-low BC may respond differently to treatment than BC with no HER2 expression (HER2-0); thus, we conducted an unplanned post hoc analysis of three randomized, pivotal
- Metastatic Breast Cancer (mBC) Treatment - HALAVEN
Metastatic Breast Cancer HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease Please see the HALAVEN full Prescribing Information I confirm that I am a US health care
|
|
|